Guideline-based and bioinformatic reassessment of lesion-associated gene and variant  pathogenicity in focal human epilepsies by Niestroj, Lisa-Marie et al.
F U L L ‐ L E NGTH OR I G I N A L R E S E ARCH
Guideline‐based and bioinformatic reassessment of
lesion‐associated gene and variant pathogenicity in focal human
epilepsies
Lisa-Marie Niestroj1 | Juanjiangmeng Du1 | Michael Nothnagel1 | Patrick May2 |
Aarno Palotie3,4,5 | Mark J. Daly4,5 | Peter Nürnberg1,6,7 | Ingmar Blümcke8 |
Dennis Lal1,4,5,9,10
1Cologne Center for Genomics, University
of Cologne, Cologne, Germany
2Luxembourg Center for Systems
Biomedicine, University Luxembourg,
Esch-sur-Alzette, Luxembourg
3Institute for Molecular Medicine
Finland, University of Helsinki, Helsinki,
Finland
4Stanley Center for Psychiatric Research,
Broad Institute of Harvard and
Massachusetts Institute of Technology,
Cambridge, Massachusetts
5Analytical Translational Genetics Unit,
Massachusetts General Hospital, Harvard
University, Boston, Massachusetts
6Center for Molecular Medicine Cologne,
University of Cologne, Cologne, Germany
7Cologne Excellence Cluster on Cellular
Stress Responses in Aging-Associated
Diseases, University of Cologne,
Cologne, Germany
8Department of Neuropathology,
University Hospital Erlangen, Erlangen,
Germany
9Genomic Medicine Institute, Lerner
Research Institute, Cleveland Clinic,
Cleveland, Ohio
10Epilepsy Center, Neurological Institute,
Cleveland Clinic, Cleveland, Ohio
Correspondence
Dennis Lal, Genomic Medicine Institute,
Cleveland Clinic, 9500 Euclid Avenue,
Cleveland, OH 44195.
Email: lald@ccf.org
Summary
Objective: Increasing availability of surgically resected brain tissue from patients
with focal epilepsy and focal cortical dysplasia or low‐grade glioneuronal tumors
has fostered large‐scale genetic examination. However, assessment of pathogenic-
ity of germ line and somatic variants remains difficult. Here, we present a state‐
of‐the‐art evaluation of reported genes and variants associated with epileptic brain
lesions.
Methods: We critically reevaluated the pathogenicity for all neuropathology‐
associated variants reported to date in the PubMed and ClinVar databases, includ-
ing 101 neuropathology‐associated missense variants encompassing 11 disease‐
related genes. We assessed gene variant tolerance and classified all identified mis-
sense variants according to guidelines from the American College of Medical
Genetics and Genomics (ACMG). We further extended the bioinformatic variant
prediction by introducing a novel gene‐specific deleteriousness ranking for predic-
tion scores.
Results: Application of ACMG guidelines and in silico gene variant tolerance
analysis classified only seven of 11 genes to be likely disease‐associated accord-
ing to the reported disease mechanism, whereas 61 (60.4%) of 101 variants of
those genes were classified as of uncertain significance, 37 (36.6%) as being
likely pathogenic, and 3 (3%) as being pathogenic.
Significance: We concluded that the majority of neuropathology‐associated vari-
ants reported to date do not have enough evidence to be classified as pathogenic.
Interpretation of lesion‐associated variants remains challenging, and application of
current ACMG guidelines is recommended for interpretation and prediction.
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1 | INTRODUCTION
Somatic gene variants have been increasingly detected and
reported in brain tissue obtained from patients with epi-
lepsy‐associated focal lesions and considered causal for the
lesion and the patient's epilepsy. A correct interpretation of
pathogenicity is essential to unravel the genetic variety of
epilepsy‐associated syndromes and serves as a basis to
develop precision treatment. The most common structural
brain lesions comprise focal cortical dysplasia (FCD) and
low‐grade epilepsy‐associated tumors,1–3 both of which
represent umbrella terms for a variety of diagnostically
related but histologically independent etiologies. FCD is a
heterogeneous group of cortical malformations accounting
for the most common structural brain lesions within the
broad spectrum of malformations of cortical develop-
ment.4–9 FCD is diagnosed in up to 18% of patients who
undergo epilepsy surgery,3 mostly affects the frontal lobe,
and can histopathologically present with a large spectrum
of abnormalities, including cortical architecture, bizarre
neuronal cell morphology, blurred gray‐white matter
boundaries, and heterotopic neurons or increased oligoden-
droglial cell densities in white matter.10 The most frequent
tumors in patients with drug‐resistant focal epilepsy starting
in the first 2 decades of life are ganglioglioma and dysem-
bryoplastic neuroepithelial tumors, accounting for 69% of
2244 tumors collected at the European Epilepsy Brain
Bank.3 Intriguingly, these tumors histopathologically pre-
sent with a variable mixture of glial and neuronal cell lin-
eages and have mostly affected the temporal lobe.11
Unlike recent large‐scale studies on rare and common
germ line variant‐associated epilepsies,12 genetic studies on
focal brain lesions comprise so far only reasonably pow-
ered hypothesis‐free exome‐wide gene discovery screens
using small cohorts of patients. Patient ascertainment is
challenging, because the disease‐associated variants are
expected to be present only in the brain or even in a frac-
tion of the lesional brain tissue.2 In addition to the limited
access to the target tissue, the prevalence of somatic mosai-
cism in the human brain of healthy individuals is not well
understood, and thus, current small cohort studies without
large control sets might lead to biased or even false conclu-
sions. Even for genuine disease‐associated genes, not all
observed variants would contribute to disease etiology. Due
to time and cost constraints, functional testing can usually
be conducted only for a minor part of variants observed in
patients. The latter represents a more general problem that
holds true for all epilepsies, because the accurate interpreta-
tion of variation in disease genes has largely lagged behind
the massive upscaling of data generation enabled by the
increased accessibility of sequencing. However, lesional
epilepsies represent a group where variant interpretation
even in established disease‐associated genes is challenging
due to the lack of somatic variant reference databases and
lack of variant interpretation guidelines as well as the
potential interplay of somatic and germ line variants.
Many recent genetic studies in, for example, familial
hypercholesterolemia13 and maturity onset diabetes of the
young14 have shown that previous disease‐associated vari-
ants are not pathogenic applying current American College
of Medical Genetics and Genomics (ACMG) guidelines.
The cost to patients when a classification is incorrect can
be a false and missed diagnosis, probably leading to misdi-
rected treatment.
To address the challenging interpretation of neu-
ropathology‐associated genes and missense variants, both
germ line and somatic, we systematically reevaluated the
pathogenicity of genes and variants that have previously
been reported to be associated with histopathologically con-
firmed epileptic brain lesions. We used recent guidelines
published by the ACMG including a novel bioinformatic
variant assessment approach. Because somatic mutations
are present only in a small fraction of brain cells, to cause
severe neuropathologies, we expect that their predicted
functional effect should be at least as severe as observed
for disease‐causing germ line variants. The variant evalua-
tion for both germ line and somatic variants was based on
ACMG guidelines. One part of the ACMG evaluation rep-
resents in silico variant functional prediction. To improve
variant evaluation, we developed a novel bioinformatic
Key Points
• Interpretation of germ line and somatic variants
obtained from patients with focal epilepsy and
histopathologically confirmed lesions remains
challenging
• In silico gene variant tolerance analysis classified
only seven of 11 genes to be likely neuropathol-
ogy-associated according to the reported disease
mechanism
• ACMG guidelines and a novel developed delete-
riousness ranking classified only 39.6% of neu-
ropathology-associated variants as pathogenic or
likely pathogenic
• Interpretation of disease-associated variants was
improved by the application of current ACMG
guidelines including bioinformatic pathogenicity
prediction
• Variants of uncertain significance remain the lar-
gest group of variants, and novel high-throughput
methods for functional testing are needed
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approach for in silico variant assessment. The guideline‐
based analysis represents state‐of‐the‐art assessment of all
reported neuropathology‐associated variants and supports
the verification and identification of disease‐associated risk
genes and variants in epilepsies. Furthermore, the evalua-
tion procedure can be reapplied to other variant sets not
exclusively restricted to epileptic neuropathologies.
2 | MATERIALS AND METHODS
2.1 | Gene and variant identification
Although the evaluation of pathogenicity for loss‐of‐func-
tion (LoF) variants (eg, full gene deletions or nonsense
variants) is straightforward, the criteria to establish
pathogenicity for missense variants rely on supportive
genetic data and functional evidence.15 We focused, there-
fore, on the guideline‐based15 interpretation of heterozy-
gous dominant acting neuropathology‐associated missense
variants and performed a PubMed‐based literature review
(https://www.ncbi.nlm.nih.gov/pubmed; accessed February
2017) to identify studies reporting genes and dominantly
acting neuropathology‐associated missense variants. First,
we used single search terms as well as two‐ or three‐word
combinations of the following keywords: “focal cortical
dysplasia,” “ganglioglioma,” “dysembryoplastic neuroep-
ithelial tumor,” “neuropathology,” “genetics,” “somatic,”
and “mutations.” Second, we collected all missense variants
in genes reported to be associated with these neuropatholo-
gies in the ClinVar database (http://www.ncbi.nlm.nih.
gov/clinvar; release: January 8, 2017) using filters
described in Appendix S1. We removed copy number, syn-
onymous, frameshift, splice site, and nonsense variants
from the dataset.
2.2 | Assessment of gene variant tolerance
We evaluated literature‐reported neuropathology‐associated
genes for variant tolerance using the pLI and missense z
conservation scores (http://exac.broadinstitute.org/) and
compared the results with the proposed pathomechanisms
in the recent literature. These scores use a depletion of
variants in a gene when compared to the expectation under
neutral evolution. The expectation has been estimated from
a population reference cohort of >60 000 individuals
(http://exac.broadinstitute.org/) as an indication of purifying
selection, rendering variants affecting these genes more
likely to be implicated in disease etiology.16 Following the
authors’ recommendations, we considered genes with pLI
scores > 0.9 as being intolerant for LoF mutations and
those with z scores > 3.09 intolerant for missense muta-
tions. We used the missense z conservation score when dis-
ease variants were reported to be missense variants in the
brain lesion, pLI when disease variants were reported to be
LoF variants, and both when missense and LoF variants
were reported to play a role in the disease etiology. Addi-
tionally, as an alternative assessment of a gene's impact on
diseases, we compared the neuropathology‐associated gene
set with cancer driver genes from Martincorena et al,17
who studied the landscape of positive and negative selec-
tion in somatic evolution in cancer and systematically cata-
loged cancer genes.
2.3 | Variant classification
All identified neuropathology‐associated somatic and germ
line missense variants were classified in accordance with
28 criteria defined by guidelines from the ACMG.15 These
ACMG guidelines were developed to set standards for the
interpretation of sequence variants primarily as an educa-
tional resource for clinical laboratory geneticists to help
them provide quality clinical laboratory services. The
ACMG recommends the use of specific standard terminol-
ogy—“pathogenic,” “likely pathogenic,” “uncertain signifi-
cance,” “likely benign,” and “benign”—to describe variants
identified in genes that cause Mendelian disorders. The
applied ACMG guidelines represent a collection of 28 cri-
teria and recommend that variant classification must be
dependent upon scientific evidence and weighted according
to the type of evidence available. ACMG criteria take func-
tional studies, segregation studies, comparison of the vari-
ant frequency in patients versus the general population,
clinical correlation between gene and clinical features of
the patient, inferences based on knowledge of the gene or
protein structure, in silico predictions, and other pieces of
evidence into account to evaluate variant pathogenicity.
We used the online tool provided by Kleinberger et al18
to aid the missense variant interpretation process and
implemented our gene‐specific deleteriousness ranking in
the ACMG guidelines by modifying the criteria
“PP3 = Multiple lines of computational evidence support a
deleterious effect on the gene or gene product.” We used
the algorithm incorporated in the tool to assign either
pathogenicity or a nondeleterious impact based on the
selected evidence categories, resulting in three positive
variant groups in our study: (1) variants of uncertain signif-
icance (VUS), (2) likely pathogenic, and (3) pathogenic
variants.
2.4 | Gene‐specific deleteriousness ranking
based on prediction scores
Current bioinformatic variant prediction scores are not
gene‐specific and do not inform whether the patient variant
score is exceptional compared to scores observed for vari-
ants from unaffected individuals in the same gene. To
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evaluate gene‐specific deleteriousness, we calculated gene‐
specific score ranks (%) of neuropathology‐associated mis-
sense variants. We sorted and ranked each patient variant
score along scores for singleton germ line missense vari-
ants in the same gene identified in the general population
from the Genome Aggregation Database (gnomAD v2.0;
http://gnomad.broadinstitute.org; February 2017). We calcu-
lated deleteriousness ranks (%) of neuropathology‐asso-
ciated missense variants for the three most commonly used
variant prediction algorithms, namely CADD,19 PolyPhen‐
2_HVAR,20 and GERP21 from dbNSFP (dbNSFP v3.3;
February 2017).22 The three scores are commonly used
bioinformatic prediction tools, whereof CADD and Poly-
Phen‐2 incorporate multiple different biological and evolu-
tionary scores and GERP exclusively scores conservation
across species. Variants that were ranked in the top 10% of
the specific gene in at least two of the three prediction
tools were considered to have multiple lines of bioinfor-
matic evidence in the ACMG pathogenicity classification.
Barplots and stacked barplots were generated with R
software, version 3.3.1.23
3 | RESULTS
3.1 | Bioinformatic assessment of gene
variant tolerance
In our literature and ClinVar review, we identified a total
of 11 genes associated with heterozygous dominant acting
neuropathology‐associated missense and LoF variants,
namely AKT3,24,25 BRAF,1 DEPDC5,26–28 FGFR1,29
MTOR,2,24,30,31 NPRL2,28,32 NPRL3,28,32 PIK3CA,24,25
PTEN,33 TSC1,34 and TSC2,27 in 12 studies. In six of 12
studies (50%), the authors sequenced the whole exome; in
three studies (25%), gene panels of 3‐14 genes were used,
and in another three studies (25%), the authors sequenced
only a single gene (Table S1). Only one‐half of 12 whole
exome sequencing and targeted sequencing studies (50%)
list detailed variant calling parameters, and one‐half list all
variants passing their filter criteria.
Based on the literature, we categorized TSC1 and PTEN
as intolerant for LoF, MTOR, PIK3CA, BRAF, and AKT3 as
intolerant for missense, and NPRL2, NPRL3, TSC2, FGFR1,
and DEPDC5 as intolerant for both (Table 1). Gene conser-
vation scores (pLI and missense z) and gene positive selec-
tion classification in cancer genomes17 indicated that only
seven (AKT3, BRAF, DEPDC5, MTOR, PIK3CA, PTEN, and
TSC1) of 11 genes showed support for association with a
severe disease in early childhood for the reported disease
mechanism by harboring significant less16 or more17 variants
than expected under neutral evolution.
Somatic and germ line disease‐associated missense vari-
ants have been reported in 10 of 11 neuropathology‐
implicated genes (Tables S2 and S4). For the remaining
gene, DEPDC5, only somatic and germ line LoF variants
have been associated with neuropathologies so far.26,35 We
next classified exclusively missense variants according to
recently published ACMG guidelines including our novel
developed gene‐specific deleteriousness ranking. The clas-
sification of LoF variants in a gene depleted for LoF vari-
ants like DEPDC5 is straightforward because of the
expected pathomechanism “haploinsufficiency.” Our litera-
ture and database review identified 101 neuropathology‐
associated missense variants in total (Figure 1A; Table S4).
Of these, 40 (located in the AKT3, BRAF, FGFR1, MTOR,
PIK3CA, and PTEN genes; 39.6%) were classified as
“likely pathogenic” or “pathogenic” by meeting a combina-
tion of the following ACMG criteria: showed a damaging
effect on the gene or gene product in functional studies,
were located in a mutational hot spot and/or critical and
well‐established functional domain, were absent from con-
trols, had received a missense z score ≥ 3.09, showed a
deleterious effect in multiple lines of computational evi-
dence, and/or were reported as pathogenic in a reputable
source (Table S4). The VUS group comprised 61 missense
variants present in all 10 neuropathology‐associated genes,
representing the majority (60.4%) of identified neuropathol-
ogy‐associated missense variants. Considering somatic and
TABLE 1 Gene variant tolerance
Gene
LoF intolerance
in controls
Functional
support
Under positive
selection in
cancer
LoF intolerance
PTEN ✓ (0.98) Yes Glioblastoma
TSC1 ✓ (1) Yes —
Missense intolerance
AKT3 ✓ (3.95) Yes —
BRAF ✓ (3.99) Yes Thyroid
MTOR ✓ (7.89) Yes Kidney
PIK3CA ✓ (5.42) Yes Glioblastoma
LoF/missense intolerance
DEPDC5a ✓/✓ (1/3.29) Yes —
FGFR1 ✓/− (0.99/2.8) Yes —
TSC2 ✓/− (1/0.89) Yes Liver
NPRL2 −/− (0.35/1.86) No —
NPRL3 −/− (0.47/0.37) No —
Depletion score analysis of 11 neuropathology‐associated genes according to
the reported pathomechanism in the literature (either LoF or missense).
✓, intolerant for reported mutations (pLI ≥ 0.9; z ≥ 3.0); −, tolerant for
reported mutation (pLI < 0.9, z < 3.09); LoF, loss of function; No, reported
pathomechanism without functional support; Yes, reported pathomechanism
with functional support, positively selected gene (driver) in cancer genome.17
aGenes were excluded from the following evaluation of variant pathogenicity,
because LoF variants were exclusively found for the phenotypes of interests.
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germ line variants separately led to virtually identical vari-
ant distributions (Table S2).
3.2 | Gene‐specific deleteriousness ranking
based on prediction scores
We developed a novel gene‐specific deleteriousness rank-
ing approach to improve the in silico missense variant pre-
diction in ACMG classification. The ranking, being based
on CADD, PolyPhen‐2, and GERP scores, identified 61.2%
(60/98) of variants as having higher pathogenic scores than
90% of gnomAD reference variants in at least one score, of
which 35% (21/60) had higher pathogenic scores than 90%
of gnomAD reference variants in two scores and 10% (6/
60) in three scores (Figure 2). Of all neuropathology‐asso-
ciated missense variants, 26.7% (27/101) showed higher
pathogenic scores than 90% of gnomAD reference variants
in the specific gene in at least two scores for which we
applied the ACMG criterion, “Multiple lines of computa-
tional evidence support a deleterious effect on the gene or
gene product.” Three variants do not have gene‐specific
deleteriousness ranks, as they are not annotated as nonsyn-
onymous variants in dbNSFP.
4 | DISCUSSION
The majority of epileptic brain lesion‐associated variants
and genes have been identified and classified before variant
interpretation guidelines were common practice. Correct
classification of variants as pathogenic or benign has a
direct benefit to patients. Aside from patient management,
certainty in the variant classification will reduce the emo-
tional stress for patients. The objective of this study was to
FIGURE 2 Gene‐specific deleteriousness ranking of neuropathology‐associated variants. A, Summary of variants with CADD, GERP, and
PolyPhen‐2 scores ranked less pathogenic than 10% of gnomAD controls (>10% in three scores), ranked within the 10th percentile of gnomAD
variants in one of the three prediction scores (<10% in one score), ranked within the 10th percentile of gnomAD variants in two of the three
prediction scores (<10% in two scores), and ranked within the 10th percentile of gnomAD variants in all three prediction scores (<10% in three
scores). B, CADD, GERP, and PolyPhen‐2 rank score summary of variants in 9 neuropathology‐associated genes (NPRL3 variants were not
annotated in dbNSFP; for DEPDC5, only loss‐of‐function variants were reported to be neuropathology‐associated)
FIGURE 1 American College of
Medical Genetics and Genomics criteria
classify neuropathology‐associated variants as
being of uncertain significance (VUS), as
being likely pathogenic (LP), or as being
pathogenic (P) variants. A, Number of
neuropathology‐associated LP, P, and VUS
variants. B, Amounts of neuropathology‐
associated LP, P, and VUS missense variants
in 10 neuropathology‐associated genes. For
DEPDC5, only loss‐of‐function variants were
reported to be neuropathology‐associated
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reevaluate pathogenicity classification of all described vari-
ants and genes associated with epileptic brain lesions
according to current guidelines and to establish the propor-
tion of variants that lack evidence to support their
pathogenicity. We performed a systematic literature review
to identify genes and missense variants identified in
patients with epilepsy‐associated focal brain lesions. We
used ACMG guidelines, including a novel developed bioin-
formatic method, for the reevaluation of genes and mis-
sense variant pathogenicity. Based on our evaluation, we
confirmed pathogenicity for only seven of 11 previously
reported genes according to the reported pathomechanism
and 40 (39.6%) of 101 reported variants.
Classification as disease genes is so far sufficiently sup-
ported for seven of the 11 tested genes when using a gene
variant tolerance assessment; AKT3, BRAF, DEPDC5,
MTOR, PTEN, PIK3CA, and TSC1 have been identified as
disease genes based on sufficient genetic and molecular
evidence. All seven genes are missense and/or LoF intoler-
ant and have been linked to the hyperactivation of the
mTOR signaling pathway by functional tests (Tables 1 and
S3). More proposed disease genes and variants associated
with neuropathologies have been identified using targeted
sequencing of only mTOR pathway genes with insufficient
evidence (no enrichment in exome, no in vivo or in vitro
support; Tables S1 and S3). Accordingly, recent studies
reporting new disease‐associated genes and variants were a
priori hypothesis‐based and potentially biased. For exam-
ple, dominantly acting LoF variants in NPRL2 and NPRL3
have been reported in neuropathology patients28 and, corre-
spondingly, haploinsufficiency as the pathomechanism has
been proposed. A hallmark of haploinsufficient genes is the
absence of LoF variants in healthy individuals.16 However,
NPRL2- and NPRL3‐affecting LoF variants have been
reported in unaffected individuals and, for both genes, no
statistically significant depletion of variants has been
observed in large‐scale databases of healthy individuals
from the general population. In contrast, at least three
papers reported germ line missense, splicing, and LoF vari-
ants in NPRL3 in patients with FCDs, but only targeted
sequencing was performed. Proof for the association of
these genes with the disease will require further statistical
enrichment and in vivo modeling.
We did not find reliable evidence for 61 missense vari-
ants to be classified as likely pathogenic by applying
ACMG classification criteria including our gene‐specific
deleteriousness ranking.
Although our results challenge the conclusions from the
authors in the individual studies, our observation is not unex-
pected. Large‐scale sequencing has entered the health care
sector, and an exponential growth of identified variants
observed in databases has begun. Only a small fraction of
variants are functionally tested for pathogenicity. It is not
surprising that 41.81% of all variants in the patient variant
database ClinVar are classified as VUS. Nevertheless, classi-
fication of variants as VUS does not rule out that the variant
might be pathogenic or benign and that future reevaluation
procedures (eg, population studies, segregation studies) or
functional tests will reveal or reject variant pathogenicity.
Tremendous advances in sequencing technologies foster
variant discovery at an accelerating pace, whereas clinical
classification of variants remains in its infancy. This is par-
ticularly true for somatic variants in brain diseases, because
reference databases for somatic variation in healthy individ-
uals are lacking. Furthermore, the consequences of somatic
mosaicism critically result from the diversity, admixture,
and developmental stage of neuroepithelial cell types in a
given brain tissue across humans. Variants, being patho-
genic when present in the germ line, could be benign when
present only in a small fraction of cells, when present in a
specific cell type where the gene is not expressed, and/or
when present with a specific expression at a specific devel-
opmental stage. Therefore, we conclude that it will be
important to include additional criteria such as the informa-
tion about gene expression in different tissues in the
ACMG guidelines in the future to improve variant evalua-
tion and that it will be especially essential to create refer-
ence databases for somatic variation in healthy individuals
with the help of single‐cell DNA sequencing.
Based on our presented data, pathogenicity interpretation
for novel missense variants is feasible only for the minority
of variants at this point. Our study further illuminates the
uncertainty of prediction of pathogenicity in the absence of
sufficient evidence defined by ACMG guidelines. ACMG
criteria including statistics or a relatively large number of
phenotypically similar patients carrying a mutation in the
same gene can give confidence of pathogenicity. In sum-
mary, consensus standards for variant assessment, together
with results from large‐scale research projects, such as the
human cell atlas36 and high‐throughput mutagenesis screen-
ing, will improve variant interpretation in the near future and
importantly will help to improve clinical decision making.
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